RT Journal Article
SR Electronic
T1 COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.16.20133140
DO 10.1101/2020.06.16.20133140
A1 Gu, Tian
A1 Mack, Jasmine A.
A1 Salvatore, Maxwell
A1 Sankar, Swaraaj Prabhu
A1 Valley, Thomas S.
A1 Singh, Karandeep
A1 Nallamothu, Brahmajee K.
A1 Kheterpal, Sachin
A1 Lisabeth, Lynda
A1 Fritsche, Lars G.
A1 Mukherjee, Bhramar
YR 2020
UL http://medrxiv.org/content/early/2020/06/18/2020.06.16.20133140.abstract
AB Importance Blacks/African-Americans are overrepresented in the number of COVID-19 infections, hospitalizations and deaths. Reasons for this disparity have not been well-characterized but may be due to underlying comorbidities or sociodemographic factors.Objective To systematically determine patient characteristics associated with racial/ethnic disparities in COVID-19 outcomes.Design A retrospective cohort study with comparative control groups.Setting Patients tested for COVID-19 at University of Michigan Medicine from March 10, 2020 to April 22, 2020.Participants 5,698 tested patients and two sets of comparison groups who were not tested for COVID-19: randomly selected unmatched controls (n = 7,211) and frequency-matched controls by race, age, and sex (n = 13,351).Main Outcomes and Measures We identified factors associated with testing and testing positive for COVID-19, being hospitalized, requiring intensive care unit (ICU) admission, and mortality (in/out-patient during the time frame). Factors included race/ethnicity, age, smoking, alcohol consumption, healthcare utilization, and residential-level socioeconomic characteristics (SES; i.e., education, unemployment, population density, and poverty rate). Medical comorbidities were defined from the International Classification of Diseases (ICD) codes, and were aggregated into a comorbidity score.Results Of 5,698 patients, (median age, 47 years; 38% male; mean BMI, 30.1), the majority were non-Hispanic Whites (NHW, 59.2%) and non-Hispanic Black/African-Americans (NHAA, 17.2%). Among 1,119 diagnosed, there were 41.2% NHW and 37.4% NHAA; 44.8% hospitalized, 20.6% admitted to ICU, and 3.8% died. Adjusting for age, sex, and SES, NHAA were 1.66 times more likely to be hospitalized (95% CI, 1.09-2.52; P=.02), 1.52 times more likely to enter ICU (95% CI, 0.92-2.52; P=.10). In addition to older age, male sex and obesity, high population density neighborhood (OR, 1.27 associated with one SD change [95% CI, 1.20-1.76]; P=.02) was associated with hospitalization. Pre-existing kidney disease led to 2.55 times higher risk of hospitalization (95% CI, 1.62-4.02; P<.001) in the overall population and 11.9 times higher mortality risk in NHAA (95% CI, 2.2-64.7, P=.004).Conclusions and Relevance Pre-existing type II diabetes/kidney diseases and living in high population density areas were associated with high risk for COVID-19 susceptibility and poor prognosis. Association of risk factors with COVID-19 outcomes differed by race. NHAA patients were disproportionately affected by obesity and kidney disease.Question What are the sociodemographic and pre-existing health conditions associated with COVID-19 outcomes and how do they differ by race/ethnicity?Findings In this retrospective cohort of 5,698 patients tested for COVID-19, high population density and comorbidities such as type II diabetes/kidney disease were associated with hospitalization, in addition to older age, male sex and obesity. Adjusting for covariates, non-Hispanic Blacks were 1.66 times more likely to be hospitalized and 1.52 times more likely to be admitted to ICUs than non-Hispanic Whites.Meaning Targeted interventions to support vulnerable populations are needed. Racial disparities existed in COVID-19 outcomes that cannot be explained after controlling for age, sex, and socioeconomic status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the University of Michigan Precision Health Initiative, University of Michigan Rogel Cancer Center, Michigan Institute of Data Science, NSF DMS 1712933 and NIH NCI P30 CA 046592-30-S3.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study protocols were reviewed and approved by the University of Michigan Medical School Institutional Review Board (IRB ID HUM00180294 and HUM00155849).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly due to patient confidentiality. The data underlying the results presented in the study are available from University of Michigan Medical School Central Biorepository for researchers who meet the criteria for access to confidential data. https://research.medicine.umich.edu/our-units/central-biorepository/get-access